Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging - Top-Institutions - MDSpire

Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging

  • By

  • Shuai Qie

  • Yasong Shi

  • Jingyun Li

  • Sicong Jia

  • Xiaoping Yin

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    GARNET trial
    GARNET trial

    N/A, N/A

    Key Differentiators

    • Oncology

  • #2

    Affiliated Hospital of Hebei University
    Affiliated Hospital of Hebei University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #3

    Baoding First Central Hospital
    Baoding First Central Hospital

    Baoding, Hebei

    Key Differentiators

    • Oncology

  • #4

    Onc.AI
    Onc.AI

    N/A, N/A

    Key Differentiators

    • Oncology

  • #5

    Bergonié Institute
    Bergonié Institute

    Bordeaux, Nouvelle-Aquitaine

    Key Differentiators

    • Oncology

Original Source(s)

Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging

  • by Shuai Qie, Yasong Shi, Jingyun Li, Sicong Jia, Xiaoping Yin

  • June 2, 2026

Related Content

County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care

Research advances of tubeless thoracic surgery for pulmonary nodules: current status and future challenges

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial